drugset / Trial / NCT00245128
Imatinib Mesylate in Treating Patients With Myelofibrosis
Phase 2
Terminated
10 enrolled
OHSU Knight Cancer Institute
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and how well it works in treating patients with myelofibrosis.
Timeline
- Start
- 2005-08
- Primary completion
- 2007-03
- Completion
- 2011-10
Outcome
Outcome not reported
Stopped: “Per PI, results from another similar study were published prior to study analysis. Negative study results were published therefore analysis was not completed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 600 mg | Oral |